A Genomic Alteration in GATA3 Affects Treatment Responses with a CDK4/6 Inhibitor Collaborating with p18INK4C Expression in Advanced Breast Carcinoma
{{output}}
Cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) with endocrine therapy benefits patients with hormone receptor (HR)-positive, human epidermal growth receptor 2 (HER2)-negative breast carcinomas. However, most tumors develop resistance to CDK4/6i during the... ...
